Business Context and Reporting Period
This Form 8-K, dated April 11, 2016, reports the consummation of a merger by NanoAntibiotics, Inc. (the "Company") with LAT Pharma, LLC ("LAT"). The transaction was structured as a statutory triangular merger where LAT became a wholly-owned subsidiary of the Company. The primary strategic objective is to continue the development of LAT's lead clinical therapeutic candidate, Continuous low-dose Infusion (CI) Terlipressin.
Key Financial Metrics and Capital Structure
The filing details a significant restructuring of the Company's equity capital rather than traditional operating financial metrics.
- Merger Consideration: The Company issued 39,820,000 shares of common stock to LAT interest holders.
- Share Retirement: Concurrently, existing shareholders agreed to retire and cancel 39,820,000 shares of common stock.
- Post-Merger Capitalization: The total number of shares issued and outstanding remained at 87,210,000.
- Ownership Structure: LAT Holders beneficially own approximately 46% of the post-merger outstanding common stock.
- Financial Statements: The filing references audited financial statements for LAT for fiscal years ending December 31, 2015 and 2014, and unaudited pro forma financial statements, but does not provide specific revenue, profit, or cash flow figures within the text of this report.
Material Changes Versus Prior Period
The most material change is the complete reconstitution of the Company's Board of Directors and executive leadership team effective at the time of the merger.
- Departures: Elliot Ehrlich resigned as Chairman, CEO, CFO, Treasurer, and Secretary. Rajah Menon resigned as President and Director.
- Appointments:
- Jonathan Adams: Appointed Chairman, Class III Director, CEO, CFO, and Treasurer. He is the founder of LAT Pharma.
- Amrit Shahzad: Appointed President, Secretary, and Class II Director.
- Cuong Do: Appointed Class I Director.
Guidance, Outlook, and Risks
Outlook: The Company's future operations will focus on the development of CI Terlipressin. The filing does not provide specific financial guidance, revenue projections, or timelines for clinical milestones.
Risks and Contingencies: The issuance of 39,820,000 shares was conducted as an unregistered sale of equity securities, relying on exemptions under Section 4(2) of the Securities Act of 1933 and Rule 506. The Company represented that the issuance did not involve a public offering and that purchasers were sophisticated investors.
Investor Verification Checklist
- Verify the specific financial performance of LAT Pharma, LLC by reviewing the audited financial statements (Exhibit 99.1) referenced but not included in the text.
- Review the unaudited pro forma financial statements (Exhibit 99.2) to understand the combined entity's financial position as of December 31, 2015.
- Confirm the terms of the Merger Agreement (Exhibit 2.1) regarding any earn-outs, additional consideration, or covenants not detailed in the summary.
- Assess the clinical development status and regulatory pathway for CI Terlipressin to evaluate the strategic value of the acquisition.